SpringerProtocols: Abstract: Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies

Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies

By: Herren Wu³

Abstract

Full Text

Download PDF (244K)

Monoclonal antibodies (MAbs) have broad therapeutic applications in cancer therapy, prevention and treatment of viral infection, immune suppression, etc. However, many well-characterized MAbs are derived from murine sources, and these antibodies have been shown to induce strong immunogenicity when administered into the human body. The ensuring human anti-mouse antibody (HAMA) response consequently can induce fast clearance of administered antibodies from serum resulting in significantly reduced efficacy. In addition, murine MAbs also have weak effector function in human, which is important for certain clinical applications. To overcome these shortcomings, humanization techniques are used to modify nonhuman MAbs for therapeutic use. Humanization can reduce and potentially eliminate the human immune response to administered foreign antibodies. It is a critical step in maximizing the usage of MAbs as therapeutic agents.

Affiliation(s): (3) MedImmune Inc., Gaithersburg, MD

Book Title: Recombinant Antibodies for Cancer Therapy: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 207 | Pub. Date: Sep-16-2002 | Page Range: 197-212 | DOI: 10.1385/1-59259-334-8:197

Subject: Cancer Research

References

Download References

1.	Morrison S. L., Johnson M. J., Herzenberg L. A., and Oi V. T. (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domain. Proc. Natl. Acad. Sci. USA 81, 6851–6855.

2.	Boulianne G. L., Hozumi N., and Shulman M. J. (1984). Production of functional chimaeric mouse/human antibody. Nature 312, 643–646.

3.	Hale G., Clark M. R., Marcus R., Winter G., Dyer M. J. S., Philips J. M., et al. (1988). Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet 2, 1394–1399. <Occurrence Type="DOI"><Handle>10.1016/S0140-6736(88)90588-0</Handle></Occurrence>

4.	Khazaeli M. B., Conry R. M., and LoBuglio A. F. (1994). Human immune response to monoclonal antibodies. J. Immunother. 15, 42–52.

5.	Jones P. T., Dear P. H., Foote J., Neuberger M. S., and Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525.

6.	Riechmann L., Clark M., Waldmann H., and Winter G. (1988). Reshaping human antibodies for therapy. Nature 332, 323–327.

7.	Foote J. and Winter G. (1992). Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224, 487–499. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(92)91010-M</Handle></Occurrence>

8.	Wu H., Beuerlein G., Nie Y., Smith H., Lee B. A., Hensler M., et al. (1998). Stepwise in vitro affinity maturation of Vitaxin, an α_vβ₃-specific humanized mAb. Proc. Natl. Acad. Sci. USA 95, 6037–6042.

9.	Wu H., Nie Y., Huse W. D., and Watkins J. D. (1999). Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294, 151–162.

10.	Chothia C., Lesk A. M., Tramontano A., Levitt M., Smith-Gill S. J., Air G., et al. (1989). Conformations of immunoglobulin hypervariable regions. Nature 342, 877–883.

11.	Foote J. and Winter G. (1992). Antibody framework residues affecting the conformation of the hypervarible loops. J. Mol. Biol. 224, 487–499. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(92)91010-M</Handle></Occurrence>

12.	Padlan E. A. (1991). A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28, 489–498. <Occurrence Type="DOI"><Handle>10.1016/0161-5890(91)90163-E</Handle></Occurrence>

13.	Harris L. and Bajorath J. (1995). Profiles for the analysis of immunoglobulin sequences: Comparison of V gene subgroups. Protein Sci. 4, 306–310.

14.	Glaser S., Kristensson K., Chilton T., and Huse W. D. (1995). Engineering the antibody combining site by codon-based mutagenesis in a filamentous phage display system, in Antibody Engineering, 2^nd ed. (Borrebaeck C. A. K., ed.), Oxford University Press, Oxford, pp. 117–131.

15.	Huse W. D., Stinchcombe T., J. Glaser, S. M., Starr L., Maclean M., et al. (1992). Application of a filamentous phage pVIII fusion protein system suitable for efficient production, screening, and mutagenesis of F(ab) antibody fragments. J. Immunol. 149, 3914–3920.

16.	Kunkel T. A. (1985). Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82, 488–492.

17.	Watkins J. D., Beuerlein G., Wu H., McFadden P. R., Pancook J. D., and Huse W. D. (1998). Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries. Anal. Biochem. 256, 169–177.

18.	Watkins J. D., Beuerlein G., Pecht G., McFadden P. R., Glaser S. M., and Huse W. D. (1997). Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay. Anal. Biochem. 253, 37–45.

19.	Glaser S. M., Yelton D. E., and Huse W. D. (1992). Antibody engineering by codonbased mutagenesis in a filamentous phage vector system. J. Immunol. 149, 3903–3913.

20.	Kabat E. A., Wu T. T., and Bilofsky H. (1977). Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. J. Biol. Chem. 252, 6609–6616.

Comments (Loading...)

Post comment/View all comments